Trial Profile
A Randomized Cross-over Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Twice Daily Oral Administration of GSK1325756, Compared to Placebo, in Healthy Subjects; and the Pharmacokinetic Profile of Twice Daily Oral Administration of GSK1325756 in Healthy Fed and Fasted Elderly Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Danirixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 12 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Dec 2010 New trial record